Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Key Inclusion Criteria:

- The ability to understand and sign a written informed consent form

- On antiretroviral regimen containing ABC/3TC FDC in combination with one third agent
for ≥ 6 consecutive months prior to screening

- Plasma HIV-1 RNA levels < 50 copies/mL for ≥ 6 months preceding the screening visit
(measured at least twice using the same assay) and without experiencing two
consecutive HIV-1 RNA above detectable levels after achieving a confirmed (two
consecutive) HIV-1 RNA below detectable levels on the current regimen in the past year

- Plasma HIV-1 RNA should be < 50 copies/mL at the screening visit

- Normal ECG

- Estimated glomerular filtration rate (GFR) ≥ 50 mL/min according to the Cockcroft
Gault formula for creatinine clearance

- Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)

- Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

- Adequate hematologic function

- Serum amylase ≤ 5 × ULN

- Males and females of childbearing potential must agree to utilize highly effective
contraception methods or be non-heterosexually active or practice sexual abstinence
from screening throughout the duration of study treatment and for 30 days following
the last dose of study drug

Key Exclusion Criteria:

- A new AIDS-defining condition diagnosed within the 30 days prior to screening

- Hepatitis B surface antigen (HBsAg) positive

- Individuals experiencing decompensated cirrhosis

- Individuals receiving ongoing treatment with bisphosphonate to treat bone disease (eg,
osteoporosis)

- Pregnant or lactating females

- Have an implanted defibrillator or pacemaker

- Current alcohol or substance use judged by the investigator to potentially interfere
with study compliance

- A history of malignancy within the past 5 years (prior to screening) or ongoing
malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
resected, non-invasive cutaneous squamous carcinoma.

- Active, serious infections (other than HIV-1 infection) requiring parenteral
antibiotic or antifungal therapy within 30 days prior to Day 1 Visit

- Any other clinical condition or prior therapy that, in the opinion of the
investigator, would make the individual unsuitable for the study or unable to comply
with dosing requirements

- Participation in any other clinical trial (including observational trials) without
prior approval

- Medications excluded due to the potential for interaction with emtricitabine (FTC),
TAF, ABC or 3TC

Note: Other protocol defined Inclusion/Exclusion criteria may apply.